PE 22-28 10 mg

Dragon Pharma PE 22-28

PE 22-28 10 mg represents a cutting-edge advancement in neuropeptide research—a meticulously synthesized fragment of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) that targets fundamental mechanisms of synaptic plasticity, cognitive enhancement, and neural protection. This research-grade peptide, comprising the bioactive sequence Gly-Ile-Ala-Gly-Ala-Ser-Asp-Arg (positions 22-28 of PACAP 1–38), offers investigators a powerful tool for exploring cAMP-mediated signaling pathways, neurotrophic modulation, and peptide-based interventions for cognitive optimization. Each vial contains 10 mg of ultra-pure PE 22-28, manufactured in Dragon Pharma's EU-certified facilities under stringent analytical controls that ensure molecular integrity and reproducible biological activity.

PE 22-28 operates through selective activation of PAC1 receptors, triggering intracellular cAMP accumulation and subsequent protein kinase A (PKA) activation—the master regulatory switch for CREB (cAMP Response Element-Binding protein) phosphorylation. This molecular cascade represents the fundamental mechanism underlying long-term potentiation (LTP), the cellular basis of learning and memory formation. Unlike broader neuropeptides that affect multiple receptor systems, PE 22-28's targeted action on the PAC1 receptor provides specific modulation of neuroplasticity pathways without significant cross-reactivity with VPAC1/VPAC2 receptors, making it an exceptional research tool for dissecting precise mechanisms of cognitive enhancement and neuroprotection. For researchers investigating nootropic interventions alongside performance compounds like Methyl-1-Test 10 or Superdrol 10, PE 22-28 offers insights into potential cognitive support mechanisms during intensive training regimens.

The scientific significance of PE 22-28 lies in its position as the minimal active fragment retaining PACAP's neurotrophic properties while exhibiting improved metabolic stability compared to the full-length peptide. Research indicates this heptapeptide fragment crosses the blood-brain barrier with greater efficiency than PACAP 1–38, exhibits resistance to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), and maintains potent cAMP-elevating activity at nanomolar concentrations. For athletic performance research, these properties suggest potential applications in enhancing motor learning, improving neuromuscular coordination, reducing central nervous system fatigue, and supporting recovery through neuroendocrine modulation. When compared to other cognitive peptides like Semax 5mg or Selank 10 mg, PE 22-28 offers a distinct mechanism focused on the fundamental molecular pathways of synaptic plasticity rather than neurotransmitter modulation.

Dragon Pharma's synthesis utilizes solid-phase peptide synthesis with Fmoc chemistry, followed by reverse-phase HPLC purification to >98% purity and mass spectrometry confirmation of molecular identity. The lyophilized formulation ensures optimal stability for research applications, easily reconstituted with sterile saline or bacteriostatic water for precise dosing in experimental models. For investigators examining the intersection of cognitive enhancement and physical performance, PE 22-28 provides a unique window into how neuropeptide signaling might optimize mind-muscle connection, enhance training adaptation through improved motor pattern encoding, and potentially mitigate the cognitive fog sometimes associated with intense training or certain performance compounds. Its research applications extend to potential synergistic effects with growth hormone secretagogues like CJC-1295 DAC, given PACAP's known cross-talk with GHRH signaling pathways.

Key Research Applications:

• Synaptic Plasticity Investigation: Models cAMP/PKA/CREB pathway activation underlying long-term potentiation and memory formation, providing insights into molecular mechanisms of learning enhancement and cognitive optimization.
• Neuroprotection & Oxidative Stress Research: Examines peptide-mediated protection against excitotoxicity, mitochondrial dysfunction, and reactive oxygen species in neural tissues under physiological stress conditions.
• Neurotrophic Factor Modulation: Studies regulation of BDNF, NGF, and GDNF expression through CREB-dependent transcription, exploring peptide influences on neuronal survival, differentiation, and connectivity.
• Cerebral Metabolism Optimization: Investigates enhancement of cerebral blood flow, glucose utilization, and mitochondrial biogenesis in neural tissues under conditions of increased metabolic demand.
• Neuroendocrine Interface Exploration: Researches cross-talk between neural PACAP signaling and pituitary hormone secretion, particularly interactions with growth hormone and prolactin regulatory pathways.

Each 2 mL vial contains 10 mg of research-grade PE 22-28 peptide, synthesized and purified under strict quality control standards in Dragon Pharma's certified European facilities for investigative use in approved research protocols.

Product Specifications

Research Guidelines

PE 22-28 is administered via subcutaneous or intraperitoneal injection in preclinical research models. Reconstitute the 10 mg vial with 1-2 mL of sterile saline or bacteriostatic water. For cognitive enhancement studies, typical research doses range from 10-100 mcg/kg body weight, administered once daily. For neuroprotection studies, pre-treatment 30-60 minutes before induced injury models is common. Injection sites include abdominal subcutaneous tissue or standard intraperitoneal locations per institutional protocols. Research suggests optimal effects in the 50-200 mcg total dose range for standard rodent models, with effects typically measurable within 30-60 minutes post-administration through behavioral assays or biochemical markers.

• Cognitive Enhancement Protocol (2-4 weeks): 50-100 mcg/kg daily to investigate learning and memory improvements in maze and conditioning paradigms. May be combined with MK 677 research to examine interactions between neuropeptide signaling and growth hormone secretion on cognitive function.
• Neuroprotection Studies (1-2 weeks): 100-200 mcg/kg administered before induced injury models (stroke, trauma, neurotoxicity). Often paired with BPC 157 research to compare neuroprotective versus general tissue repair mechanisms.
• Motor Learning Investigations (3-4 weeks): 75-150 mcg/kg during skill acquisition phases to study neuromuscular adaptation. Can be examined alongside IGF-1 LR3 research to differentiate neural versus muscular components of motor learning.

Experimental Design Considerations:

For studies examining cognitive effects: Utilize standardized behavioral tests (Morris water maze, passive avoidance, novel object recognition) with proper controls. Biochemical endpoints should include hippocampal cAMP levels, CREB phosphorylation, and BDNF expression. When researching potential athletic applications: Consider motor coordination tests, reaction time measurements, and central fatigue assessment during prolonged exercise models. For investigations involving other compounds like Clenbuterol or T3, monitor potential interactions between metabolic state and cognitive function.

Safety & Monitoring Parameters:

Research models should be monitored for potential hemodynamic effects (PACAP receptors mediate vasodilation), glucose metabolism changes, and core temperature fluctuations. Behavioral observations should include activity levels, grooming behavior, and social interactions. When studying alongside stimulant compounds like Helios or Salbutamol, careful cardiovascular monitoring is advised. Research suggests PE 22-28 is well-tolerated in preclinical models at therapeutic doses, with no significant adverse effects reported in controlled studies.

Storage Instructions

Unreconstituted: Store lyophilized PE 22-28 vials at -20°C (-4°F) for long-term stability (up to 24 months). The peptide fragment maintains stability under these conditions with minimal degradation. For short-term storage (up to 30 days), refrigeration at 2-8°C (36-46°F) is acceptable. Avoid repeated freeze-thaw cycles as this can lead to peptide aggregation and reduced biological activity.

Reconstituted: After mixing with appropriate vehicle (sterile saline recommended for research), use immediately for optimal activity. If necessary, reconstituted solution can be stored at 2-8°C (36-46°F) for up to 7 days, though some activity loss may occur after 48 hours. For behavioral studies requiring precise dosing, fresh preparation before each administration is strongly recommended.

Research Handling Notes: Use aseptic technique for all reconstitution and administration procedures. Protect from light exposure using amber vials or aluminum foil. Gently swirl to dissolve—avoid vortexing which can introduce oxidation. Aliquot into single-use portions if planning multiple administrations to minimize freeze-thaw cycles. Document storage conditions and duration as part of research methodology.